{"id":32823,"date":"2026-07-08T17:00:00","date_gmt":"2026-07-08T15:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=7fa5ad7a4ed30ecbac625fffb18b7de5"},"modified":"2026-07-08T17:00:00","modified_gmt":"2026-07-08T15:00:00","slug":"emd-serono-announces-fda-breakthrough-therapy-designation-for-enpatoran-in-lupus-patients-with-active-skin-manifestations","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=32823","title":{"rendered":"EMD Serono Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients with Active Skin Manifestations"},"content":{"rendered":"<ul class=\"bwlistdisc\">\n<li>\n<b>Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapies<\/b><\/li>\n<li>\n<b>FDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestations<\/b><\/li>\n<li>\n<b>Enpatoran's potential to go beyond current treatment standards in lupus prompted FDA's breakthrough designation, which is designed to expedite drug development and review<\/b><\/li>\n<\/ul><p>\n<b><span class=\"bwuline\">Not intended for media outside the U.S. or Canada<\/span><\/b><\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260706743878\/en\/2004114\/4\/EMD_Logo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260706743878\/en\/2004114\/22\/EMD_Logo.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260706743878\/en\/2004114\/4\/EMD_Logo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260706743878\/en\/2004114\/21\/EMD_Logo.jpg\" \/><\/a><p>BOSTON--(BUSINESS WIRE)--EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7\/8 inhibitor, designed to modulate pathways central to lupus-related inflammation.<\/p><p>\n\u201cFor the 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burden, the lack of targeted treatment makes the disease hard to control,\u201d said David Weinreich, MD, MBA, Global Head of R&amp;D and Chief Medical Officer for the Healthcare business of Merck KGaA, Darmstadt, Germany. \u201cThis Breakthrough Therapy designation demonstrates that enpatoran has the potential to redefine how we approach lupus, by addressing the visible burden of rash, while potentially driving benefit beyond the skin. We look forward to working with the FDA to potentially bring this much-needed option to patients as quickly as possible.\u201d<\/p><p>\nThe FDA Breakthrough Therapy designation is supported by results from the Phase 2 WILLOW study, a multicenter, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the safety and efficacy of orally administered enpatoran. The trial used an innovative basket and adaptive study design including patients with both CLE (Cutaneous Lupus Erythematosus) and SLE (Systemic Lupus Erythematosus). The results demonstrated that enpatoran delivered clinically meaningful improvements of lupus symptoms, particularly in patients with active cutaneous manifestations.<\/p><p>\nAdditionally, Merck KGaA, Darmstadt, Germany recently initiated the ELOWEN 1 and ELOWEN 2 studies, a global Phase 3 program evaluating the therapy\u2019s impact on both cutaneous and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity.<\/p><p>\nLupus is a chronic autoimmune disease that can affect multiple organ systems, including the skin, joints, kidneys, and central nervous system. Skin manifestations, which can present as inflamed, photosensitive lesions on the face, scalp and other areas, may be life-altering and are sometimes irreversible on their own. But, despite skin manifestations being the first sign of disease in nearly one-third (29%) of lupus cases,<sup>1<\/sup> many patients still do not achieve adequate disease control.<sup>2<\/sup><\/p><p>\nFDA Breakthrough Therapy designation is a process aimed at expediting the development and review of drugs for serious conditions, where the preliminary clinical evidence indicates that the drug may offer a substantial improvement over available therapy.<\/p><p>\n<b>About enpatoran<\/b><\/p><p>\nEnpatoran is an investigational, oral, selective inhibitor of toll-like receptors 7 and 8 (TLR7\/8), which play a key role in immune pathways involved in lupus. Enpatoran has the potential to be the first targeted therapy for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standards of care for patients with CLE and SLE. Enpatoran is currently under clinical investigation and has not been approved for any use anywhere in the world.<\/p><p>\n<b>About the Phase 3 ELOWEN Program<\/b><\/p><p>\nELOWEN-1 (<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07332481&amp;esheet=54565705&amp;newsitemid=20260706743878&amp;lan=en-US&amp;anchor=NCT07332481&amp;index=1&amp;md5=ff0b25314f8f697be977c36214781a43\" rel=\"nofollow\" shape=\"rect\">NCT07332481<\/a>) and ELOWEN-2 (<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07355218&amp;esheet=54565705&amp;newsitemid=20260706743878&amp;lan=en-US&amp;anchor=NCT07355218&amp;index=2&amp;md5=3ca8883ba7490525cf7eefda67da2fa2\" rel=\"nofollow\" shape=\"rect\">NCT07355218<\/a>) are two global randomized, double-blind, placebo-controlled Phase 3 studies evaluating enpatoran taken twice daily versus placebo, on top of standard of care, in patients with lupus who have active cutaneous manifestations. The ELOWEN studies will be conducted in 266 sites in 26 countries. Each study will recruit approximately 200 lupus participants, and the primary endpoint will be a change in CLASI-A from baseline.<\/p><p>\n<b>About Lupus Erythematosus<\/b><\/p><p>\nLupus erythematosus is a chronic autoimmune disease characterized by inflammation that can affect multiple organs and systems in the body. The disease is heterogeneous, with symptoms ranging from mild to life-threatening, and often follows a relapsing-remitting course.<\/p><p>\nCutaneous manifestations are common (72-85%) in patients and can occur alongside or independently of systemic involvement. Beyond their physical presentation, they are associated with increased disease burden, including scarring, psychological impact and reduced quality of life.<\/p><p>\nLupus disproportionately affects women and people of color, and many patients continue to experience unmet medical needs due to insufficient disease control or treatment-related side effects.<\/p><p>\n<b>About EMD Serono, Inc.<\/b><\/p><p>\nEMD Serono - the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada - aspires to create, improve and prolong life for people living with difficult-to-treat conditions like infertility, multiple sclerosis and cancer. The business is imagining the future of healthcare by working to translate the discovery of molecules into potentially meaningful outcomes for people with serious unmet medical needs. EMD Serono\u2019s global roots go back more than 350 years with Merck KGaA, Darmstadt, Germany. Today, the business has approximately 1,050 employees around the country with commercial, clinical and research operations in Massachusetts. <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.emdserono.com&amp;esheet=54565705&amp;newsitemid=20260706743878&amp;lan=en-US&amp;anchor=www.emdserono.com&amp;index=3&amp;md5=e25abf8da2acb7427857622207cdcb8d\" rel=\"nofollow\" shape=\"rect\">www.emdserono.com<\/a>.<\/p><p>\n<b>About Merck KGaA, Darmstadt, Germany<\/b><\/p><p>\nMerck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people\u2019s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices \u2013 the company is everywhere. In 2025, Merck KGaA, Darmstadt, Germany, generated sales of \u20ac 21.1 billion in 65 countries.<\/p><p>\nThe company holds the global rights to the name and trademark \u201cMerck\u201d internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company\u2019s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.<\/p><p>\nAll Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada, please go to <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.emdgroup.com%2Fen%2Fmedia-center%2Fpress-release-subscription.html&amp;esheet=54565705&amp;newsitemid=20260706743878&amp;lan=en-US&amp;anchor=www.emdgroup.com%2Fsubscribe&amp;index=4&amp;md5=58860342737f9394a603d326817d601d\" rel=\"nofollow\" shape=\"rect\">www.emdgroup.com\/subscribe<\/a> to register online, change your selection or discontinue this service.<\/p><p>\n<b>Merck KGaA, Darmstadt, Germany in Neurology and Immunology<\/b><\/p><p>\nMerck KGaA, Darmstadt, Germany has a long-standing legacy in neurology and immunology. The company\u2019s current neurology portfolio includes two products for the treatment of relapsing MS. Merck KGaA, Darmstadt, Germany aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck KGaA, Darmstadt, Germany\u2019s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including lupus and generalized myasthenia gravis (gMG).<\/p><p>\n<sup>1<\/sup> Childs B and Merola JF. From the Masterclasses in Dermatology 2025 Meeting: Practical Approaches to Cutaneous and Systemic Lupus for Dermatologists. J Clin Aesthet Dermatol. 2025;18(10):40\u201347.<\/p><p>\n<sup>2<\/sup> Kandane-Rathnayake R, Louthrenoo W, Hoi A, et al. \u2018Not at target\u2019: prevalence and consequences of inadequate disease control in systemic lupus erythematosus\u2014a multinational observational cohort study. Arthritis Res Ther. 2022;24(1):70.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\nSebastian Roos\n<br\/><a  href=\"mailto:sebastian.roos@emdgroup.com\" rel=\"nofollow\" shape=\"rect\">Sebastian.roos@emdgroup.com<\/a><br\/>Phone: +49 151 14 54 1721<\/p>","protected":false},"excerpt":{"rendered":"<p>Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapies<\/p>\n<p>FDA&rsquo;s decision was supported by Phase 2 WILLOW study results, which demonstrated me&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-32823","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/32823","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32823"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/32823\/revisions"}],"predecessor-version":[{"id":32824,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/32823\/revisions\/32824"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32823"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32823"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32823"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}